• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Secukinumab
    1 Drug classified under this active ingredient


    All the Active Ingredient Drugs

    Cosentyx 150 mg
    Novartis
    RX
    partial basket chart
    Cosentyx 150 mg

    Interleukin Inhibitor. Secukinumab 150 mg.
    VIAL(pwdr. for sol. for inj.): 1×6ml.
    PRE FILL. PEN/SYR (sol. for inj.): 1, 2×1ml Plaque psorias.: 300 mg by SC inj. with init. dosing at Weeks 0, 1, 2, 3 and 4, follow. by mnthly. mainten. dosing. Each 300 mg dose is given as two SC inj. of 150 mg. Psoriat. arthrit.: For pts. with concom. moder.-sev. plaque psorias. or who are anti-TNFα inadeq. responders (IR): 300 mg by SC inj. with init. dosing at Weeks 0, 1, 2, 3 and 4, follow. by mnthly. mainten. dosing. Each 300 mg dose is given as two SC inj. of 150 mg.
    For other pts.: dose is 150 mg by SC inj. with init. dosing at Weeks 0, 1, 2, 3 and 4, follow. by monthly mainten. dosing. Ankylos. spondylit.: 150 mg by SC inj. with init. dosing at Weeks 0, 1, 2, 3 and 4, follow. by mnthly. mainten. dosing.
    For all of the above indications, usually achieved within 16 wks. of tmt. Consider. should be given to discont. tmt. in pts. who have shown no response by 16 wks. of tmt. Some pts. with an init. partial response may subseq. improve with continued tmt. beyond 16 wks.
    Plaque psorias.: Tmt. of moder.- sev. plaque psorias. in adult. who are candidates for system. ther.
    Psoriat. arthrit.: Alone or in comb. with methotrexate (MTX): tmt. of active psoriat. arthrit. in adult pts. when the response to previous dis.-modif. anti-rheumatic drug (DMARD) ther. has been inadeq.
    Ankylosing spondylitis: Tmt. of active ankylos. spondylitis in adult. who have responded inadeq. to convent. ther.
    C/I: Severe hypersens. Clinical. important, active infec. (e.g. active tuberculosis).

    CLOSE